Nevertheless, in line with existing data from both other tumor entities and HNSCC patients, our results support the association between elevated markers of systemic inflammation and poorer outcomes in anti-PD-1 immunotherapy for HNSCC. The gene discussed is PDCD1; the disease is neoplasm.